Cyllene Therapeutics Secures €33 Million in Series C Funding
Cyllene Therapeutics, a Paris-based biotech firm specializing in precision genetic medicine, has successfully closed a €33 million Series C funding round. The financing was led by new investors GordonMD Global Investments® LP and M Ventures, with participation from existing investors Andera Partners SAS, Bpifrance Investissement, and Lamond Ventures LLC.
Company Background and Leadership
Cyllene Therapeutics, formerly known as EG 427, focuses on developing innovative treatments for severe chronic conditions, particularly in the field of neuro-urology. The company is led by Philippe Chambon, who serves as both Founder, Chairman, and CEO. The founding team also includes Alberto Epstein (Founder & CSO), Charles Joussain, François Giuliano, and Pierre Denys. Reflecting on the recent funding, Chambon stated: "This financing marks a defining moment for our company as we continue advancing EG110A toward later-stage clinical development."
Strategic Use of Funds
The newly acquired funds will be instrumental in propelling the clinical development of EG110A, Cyllene's leading precision genetic medicine candidate. EG110A is being developed for the treatment of neurogenic detrusor overactivity (NDO), a severe chronic condition in neuro-urology. Additionally, the funding will support the expansion of Cyllene's HERMES non-replicating HSV-1 platform, which is designed for safe and targeted delivery of therapeutic DNA.
Expanding the Pipeline
The Series C funding will also enable Cyllene Therapeutics to broaden its pipeline of drug candidates. The company aims to leverage its HERMES technology to target a wider range of indications beyond NDO, thereby increasing its impact in the field of genetic medicine.
Conclusion
With this significant investment, Cyllene Therapeutics is well-positioned to advance its clinical programs and expand its innovative pipeline. The company's strategic focus on precision genetic medicine and its commitment to addressing chronic conditions highlight its potential influence on the future of healthcare.